Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Exertional Desaturation and Prescription of Ambulatory Oxygen Therapy in Interstitial Lung Disease.

Khor YH, Goh NS, Glaspole I, Holland AE, McDonald CF.

Respir Care. 2018 Oct 30. pii: respcare.06334. doi: 10.4187/respcare.06334. [Epub ahead of print]

PMID:
30377245
2.

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Macansh S, Grainge C, Keir GJ, Hayen A, Henderson D, Klebe S, Heinze SB, Miller A, Rouse HC, Duhig E, Cooper WA, Mahar AM, Ellis S, McCormack SR, Ng B, Godbolt DB, Corte TJ.

Respirology. 2018 Oct 17. doi: 10.1111/resp.13427. [Epub ahead of print]

PMID:
30328644
3.

Understanding the patient's experience of care in idiopathic pulmonary fibrosis.

Burnett K, Glaspole I, Holland AE.

Respirology. 2018 Oct 3. doi: 10.1111/resp.13414. [Epub ahead of print] No abstract available.

PMID:
30282111
4.

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.

Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M.

Lancet Respir Med. 2018 Sep 14. pii: S2213-2600(18)30339-4. doi: 10.1016/S2213-2600(18)30339-4. [Epub ahead of print]

PMID:
30224318
5.

Short- and Long-Term Reliability of the 6-Minute Walk Test in People With Idiopathic Pulmonary Fibrosis.

Holland AE, Hill CJ, Dowman L, Glaspole I, Goh N, Lee AL, McDonald CF.

Respir Care. 2018 Aug;63(8):994-1001. doi: 10.4187/respcare.05875. Epub 2018 Jun 26.

PMID:
29945909
6.

Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary.

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, Jones LJ, Hopkins P, Allan HM, Glaspole I, Corte TJ.

Med J Aust. 2018 Feb 5;208(2):82-88.

PMID:
29385965
7.

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.

Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ.

BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.

8.

Cyclophosphamide for connective tissue disease-associated interstitial lung disease.

Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN.

Cochrane Database Syst Rev. 2018 Jan 3;1:CD010908. doi: 10.1002/14651858.CD010908.pub2. Review.

PMID:
29297205
9.

The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

Prasad JD, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Lake F, Hopkins PMA, Corte TJ, Allan H, Glaspole IN.

Respirology. 2017 Oct;22(7):1459-1472. doi: 10.1111/resp.13163. Epub 2017 Sep 10.

PMID:
28891101
10.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

PMID:
28860269
11.

Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh N, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford H, Chapman S, Reynolds PN, Glaspole I, Beatson D, Jones L, Hopkins P, Corte TJ.

Respirology. 2017 Oct;22(7):1436-1458. doi: 10.1111/resp.13146. Epub 2017 Aug 27. Erratum in: Respirology. 2018 Jan;23 (1):116.

PMID:
28845557
12.

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis.

Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE.

Eur Respir J. 2017 Aug 17;50(2). pii: 1700168. doi: 10.1183/13993003.00168-2017. Print 2017 Aug. No abstract available.

PMID:
28818883
13.

Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence.

Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, Holland AE.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170072. doi: 10.1183/16000617.0072-2017. Print 2017 Sep 30. No abstract available.

14.

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.

Parker JM, Glaspole IN, Lancaster LH, Haddad TJ, She D, Roseti SL, Fiening JP, Grant EP, Kell CM, Flaherty KR.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):94-103. doi: 10.1164/rccm.201704-0784OC.

PMID:
28787186
15.

Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: A randomized crossover trial.

Khor YH, McDonald CF, Hazard A, Symons K, Westall G, Glaspole I, Goh NSL, Holland AE.

Respirology. 2017 Nov;22(8):1598-1603. doi: 10.1111/resp.13083. Epub 2017 May 23.

PMID:
28544460
16.

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.

Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ.

Respirology. 2017 Nov;22(8):1592-1597. doi: 10.1111/resp.13084. Epub 2017 May 23.

PMID:
28544079
17.

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Keir GJ, Hayen A, Cooper WA, Mahar AM, Ellis S, Macansh S, Corte TJ.

Eur Respir J. 2017 Feb 23;49(2). pii: 1601592. doi: 10.1183/13993003.01592-2016. Print 2017 Feb. Erratum in: Eur Respir J. 2017 Mar 29;49(3):.

18.

Oxygen therapy for interstitial lung disease: a systematic review.

Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, Holland AE.

Eur Respir Rev. 2017 Feb 21;26(143). pii: 160080. doi: 10.1183/16000617.0080-2016. Print 2017 Jan. Review.

19.

The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial.

Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, Glaspole I, Goh NSL, Southcott AM, Burge AT, Gillies R, Martin A, Holland AE.

Thorax. 2017 Jul;72(7):610-619. doi: 10.1136/thoraxjnl-2016-208638. Epub 2017 Feb 17.

PMID:
28213592
20.

Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry.

Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, Macansh S, Mahar A, Moodley YP, Paul E, Reynolds PN, Walters EH, Zappala CJ, Corte TJ.

Respirology. 2017 Jul;22(5):950-956. doi: 10.1111/resp.12989. Epub 2017 Feb 6.

21.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
22.

Clinical impact of the interstitial lung disease multidisciplinary service.

Jo HE, Glaspole IN, Levin KC, McCormack SR, Mahar AM, Cooper WA, Cameron R, Ellis SJ, Cottee AM, Webster SE, Troy LK, Torzillo PJ, Corte P, Symons KM, Taylor N, Corte TJ.

Respirology. 2016 Nov;21(8):1438-1444. doi: 10.1111/resp.12850. Epub 2016 Jul 18.

PMID:
27427515
23.

Idiopathic pulmonary fibrosis: an Australian perspective.

Prasad J, Holland AE, Glaspole I, Westall G.

Intern Med J. 2016 Jun;46(6):663-8. doi: 10.1111/imj.13078. Review.

PMID:
27257148
24.

Assessing the feasibility of a web-based registry for multiple orphan lung diseases: the Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience.

Casamento K, Laverty A, Wilsher M, Twiss J, Gabbay E, Glaspole I, Jaffe A; On behalf the Pulmonary Interstitial Vascular Organisational Taskforce (PIVOT) of Lung Foundation Australia.

Orphanet J Rare Dis. 2016 Apr 18;11:42. doi: 10.1186/s13023-016-0389-z.

25.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

26.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

27.

Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres.

Jo HE, Corte TJ, Moodley Y, Levin K, Westall G, Hopkins P, Chambers D, Glaspole I.

BMC Pulm Med. 2016 Feb 1;16:22. doi: 10.1186/s12890-016-0179-3.

28.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

29.

Reliability of the hand held dynamometer in measuring muscle strength in people with interstitial lung disease.

Dowman L, McDonald CF, Hill CJ, Lee A, Barker K, Boote C, Glaspole I, Goh N, Southcott A, Burge A, Ndongo R, Martin A, Holland AE.

Physiotherapy. 2016 Sep;102(3):249-55. doi: 10.1016/j.physio.2015.10.002. Epub 2015 Oct 22.

PMID:
26596172
30.

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW.

Chest. 2015 Jul;148(1):196-201. doi: 10.1378/chest.14-2817.

31.

Be honest and help me prepare for the future: What people with interstitial lung disease want from education in pulmonary rehabilitation.

Holland AE, Fiore JF Jr, Goh N, Symons K, Dowman L, Westall G, Hazard A, Glaspole I.

Chron Respir Dis. 2015 May;12(2):93-101. doi: 10.1177/1479972315571925. Epub 2015 Feb 16.

PMID:
25687210
32.

Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project.

Moodley Y, Goh N, Glaspole I, Macansh S, Walters EH, Chapman S, Hopkins P, Reynolds PN, Zappala C, Cooper W, Mahar A, Ellis S, McCormack S, Darbishire W, Wood-Baker R, Corte TJ; Australian IPF Registry Steering Committee.

Respirology. 2014 Oct;19(7):1088-91. doi: 10.1111/resp.12358. Epub 2014 Aug 14.

33.

Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease.

Holland AE, Fiore JF Jr, Bell EC, Goh N, Westall G, Symons K, Dowman L, Glaspole I.

Respirology. 2014 Nov;19(8):1215-21. doi: 10.1111/resp.12360. Epub 2014 Aug 12.

34.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.

N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.

35.

Prevalence and prognosis of unclassifiable interstitial lung disease.

Troy L, Glaspole I, Goh N, Zappala C, Hopkins P, Wilsher M, Moodley Y, Corte T.

Eur Respir J. 2014 May;43(5):1529-30. doi: 10.1183/09031936.00003414. No abstract available.

36.

Comment on: A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis: reply.

Glaspole I, Hoy R, Ryan P.

Rheumatology (Oxford). 2014 Jun;53(6):1155. doi: 10.1093/rheumatology/keu144. Epub 2014 Mar 27. No abstract available.

PMID:
24681841
37.

Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease.

Holland AE, Hill CJ, Glaspole I, Goh N, Dowman L, McDonald CF.

Respir Med. 2013 Jul;107(7):1066-72. doi: 10.1016/j.rmed.2013.04.002. Epub 2013 May 10.

38.

A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.

Glaspole IN, Hoy RF, Ryan PF.

Rheumatology (Oxford). 2013 Dec;52(12):2302-4. doi: 10.1093/rheumatology/ket175. Epub 2013 May 9. No abstract available.

PMID:
23661426
39.

The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial.

Dowman L, McDonald CF, Hill C, Lee A, Barker K, Boote C, Glaspole I, Goh N, Southcott A, Burge A, Ndongo R, Martin A, Holland AE.

BMC Pulm Med. 2013 Feb 1;13:8. doi: 10.1186/1471-2466-13-8.

40.

Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?

Corte TJ, Goh NS, Glaspole IN, Zappala CJ, Hopkins PM, Wilsher ML.

Thorax. 2013 May;68(5):491-2. doi: 10.1136/thoraxjnl-2012-203114. Epub 2013 Jan 23. No abstract available.

PMID:
23345573
41.

Predictors of benefit following pulmonary rehabilitation for interstitial lung disease.

Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF.

Respir Med. 2012 Mar;106(3):429-35. doi: 10.1016/j.rmed.2011.11.014. Epub 2011 Dec 17.

42.

Clinical allergy to hazelnut and peanut: identification of T cell cross-reactive allergens.

Glaspole IN, de Leon MP, Prickett SR, O'Hehir RE, Rolland JM.

Int Arch Allergy Immunol. 2011;155(4):345-54. doi: 10.1159/000321268. Epub 2011 Feb 22.

PMID:
21346364
43.

Differentiating between IPF and NSIP.

Glaspole I, Goh NS.

Chron Respir Dis. 2010 Aug;7(3):187-95. doi: 10.1177/1479972310376205. Review.

PMID:
20688895
44.

Anaphylaxis to lemon soap: citrus seed and peanut allergen cross-reactivity.

Glaspole IN, de Leon MP, Rolland JM, O'Hehir RE.

Ann Allergy Asthma Immunol. 2007 Mar;98(3):286-9.

PMID:
17378262
45.

Potential food allergens in wine: double-blind, placebo-controlled trial and basophil activation analysis.

Rolland JM, Apostolou E, Deckert K, de Leon MP, Douglass JA, Glaspole IN, Bailey M, Stockley CS, O'Hehir RE.

Nutrition. 2006 Sep;22(9):882-8.

PMID:
16928473
46.

IgE cross-reactivity between the major peanut allergen Ara h 2 and tree nut allergens.

de Leon MP, Drew AC, Glaspole IN, Suphioglu C, O'Hehir RE, Rolland JM.

Mol Immunol. 2007 Jan;44(4):463-71. Epub 2006 Mar 31.

PMID:
16580071
47.

Functional analysis of cross-reactive immunoglobulin E antibodies: peanut-specific immunoglobulin E sensitizes basophils to tree nut allergens.

de Leon MP, Drew AC, Glaspole IN, Suphioglu C, Rolland JM, O'Hehir RE.

Clin Exp Allergy. 2005 Aug;35(8):1056-64.

PMID:
16120088
48.

Characterization of the T-cell epitopes of a major peanut allergen, Ara h 2.

Glaspole IN, de Leon MP, Rolland JM, O'Hehir RE.

Allergy. 2005 Jan;60(1):35-40.

PMID:
15575928
49.

Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome).

Morgan SJ, Prince HM, Westerman DA, McCormack C, Glaspole I.

Leuk Lymphoma. 2003 Sep;44(9):1623-5. Review.

PMID:
14565669
50.

Immunological analysis of allergenic cross-reactivity between peanut and tree nuts.

de Leon MP, Glaspole IN, Drew AC, Rolland JM, O'Hehir RE, Suphioglu C.

Clin Exp Allergy. 2003 Sep;33(9):1273-80.

PMID:
12956750

Supplemental Content

Loading ...
Support Center